keyword
MENU ▼
Read by QxMD icon Read
search

melanoma Stage 3

keyword
https://www.readbyqxmd.com/read/27928805/-treatment-and-prognosis-analysis-of-64-cases-with-anorectal-malignant-melanoma
#1
Wei Pei, Haitao Zhou, Jianan Chen, Qian Liu
OBJECTIVE: To explore the surgical treatment patterns and clinicopathological prognostic factors of anorectal malignant melanoma (ARMM). METHODS: The medical records and follow-up data of 64 patients with anorectal malignant melanoma undergoing surgical treatment from August 1972 to December 2015 were collected and analyzed retrospectively. Distant metastasis was discovered in 4 patients when diagnosis, of whom 3 underwent abdominoperineal resection(APR), the other underwent wide local excision (WLE)...
November 25, 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27926587/anti-programmed-cell-death-protein-1-tolerance-and-efficacy-after-ipilimumab-immunotherapy-observational-study-of-39-patients
#2
Reyhan Amode, Barouyr Baroudjian, Anita Kowal, Majdi Jebali, Clara Allayous, Martine Bagot, Nika Madjlessi, Jennifer Roux, Manuelle Viguier, Nicole Basset Seguin, Raphaël Porcher, Cécile Pagès, Céleste Lebbé
In patients with ipilimumab (IPI)-refractory melanoma, the anti-programmed cell death proteins 1 (PD1s) nivolumab (NIV) and pembrolizumab (PEM) are considered to be a new standard of treatment. Few data are available on anti-PD1 safety in patients who develop IPI-related severe adverse events (AEs) (grade≥3). The aim of this study was to compare the anti-PD1 safety and efficacy in patients with previous severe toxicity to IPI versus in those showing moderate and no previous IPI-related AEs. This single institution-based observational study included all patients treated with anti-PD1 (PEM or NIV) and previously treated with IPI for unresectable stage III or IV melanoma...
December 6, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27923593/diagnosis-and-treatment-of-in-transit-melanoma-metastases
#3
REVIEW
A Testori, S Ribero, V Bataille
In transit metastases (ITM) from extremity or trunk melanomas are subcutaneous or cutaneous lymphatic deposits of melanoma cells, distant from the primary site but not reaching the draining nodal basin. Superficial ITM metastases develop in 5-10% of melanoma patients and are thought to be caused by cells spreading along lymphatics; ITM appear biologically different from distant cutaneous metastases, these probably due to a haematogenous dissemination. The diagnosis is usually clinical and by patients, but patients need to be adequately educated in the recognition of this clinical situation...
October 27, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27919243/tumour-stage-distribution-and-survival-of-malignant-melanoma-in-germany-2002-2011
#4
Olaf Schoffer, Stefanie Schülein, Gerlinde Arand, Hans Arnholdt, Dieter Baaske, Ralf C Bargou, Nikolaus Becker, Matthias W Beckmann, Yves Bodack, Beatrix Böhme, Tayfun Bozkurt, Regine Breitsprecher, Andre Buchali, Elke Burger, Ulrike Burger, Klaus Dommisch, Gudrun Elsner, Karin Fernschild, Ulrike Flintzer, Uwe Funke, Michael Gerken, Hubert Göbel, Norbert Grobe, Vera Gumpp, Lucie Heinzerling, Lana Raffaela Kempfer, Alexander Kiani, Monika Klinkhammer-Schalke, Sabine Klöcking, Ute Kreibich, Katrin Knabner, Peter Kuhn, Stine Lutze, Uwe Mäder, Tanja Maisel, Jan Maschke, Martin Middeke, Andreas Neubauer, Antje Niedostatek, Anabelle Opazo-Saez, Christoph Peters, Beatrice Schell, Gerhard Schenkirsch, Harald Schmalenberg, Peter Schmidt, Constanze Schneider, Birgit Schubotz, Anika Seide, Paul Strecker, Sabine Taubenheim, Matthias Wackes, Steffen Weiß, Claudia Welke, Carmen Werner, Christian Wittekind, Jörg Wulff, Heike Zettl, Stefanie J Klug
BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. METHODS: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival...
December 5, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27886404/adipophilin-expression-in-cutaneous-malignant-melanoma
#5
Masakazu Fujimoto, Ibu Matsuzaki, Yuki Yamamoto, Akihiko Yoshizawa, Kenji Warigaya, Yoshifumi Iwahashi, Fumiyoshi Kojima, Fukumi Furukawa, Shin-Ichi Murata
BACKGROUND: The lipogenic pathway is upregulated in cancer cells, including melanomas. However, the pathological significance of cellular lipids in melanocytic lesions has yet to be determined. In this study, we evaluated intracytoplasmic lipid droplets in melanocytic nevi (MNs) and malignant melanomas via immunohistochemical analysis of adipophilin (ADP), which coats lipid droplets. METHODS: One hundred primary cutaneous melanocytic lesions (33 MNs, 17 melanomas in situ [MIS], and 50 invasive melanomas [IMs]) were immunostained for ADP...
November 25, 2016: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/27882308/prognostic-impact-of-autophagy-biomarkers-for-cutaneous-melanoma
#6
REVIEW
Diana Y L Tang, Robert A Ellis, Penny E Lovat
Prognosis and survival for malignant melanoma is highly dependent on early diagnosis and treatment. While the American Joint Committee on Cancer (AJCC) criterion provides a means of staging melanomas and guiding treatment approaches, it is unable to identify the risk of disease progression of early stage tumors or provide reliable stratification for novel adjuvant therapies. The demand for credible prognostic/companion biomarkers able to identify high-risk melanoma subgroups as well as guide more effective personalized/precision-based therapy is therefore of paramount importance...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27878363/improvement-of-overall-survival-in-stage-iv-melanoma-patients-during-2011-2014-analysis-of-real-world-data-in-441-patients-of-the-german-central-malignant-melanoma-registry-cmmr
#7
Andrea Forschner, Felizitas Eichner, Teresa Amaral, Ulrike Keim, Claus Garbe, Thomas Kurt Eigentler
BACKGROUND: During 2011 and 2014, new treatment modalities like tyrosine kinase inhibitors and checkpoint inhibitors were introduced into the therapy of metastatic melanoma. This study addresses the question whether overall survival (OS) of metastatic melanoma patients has already been improved in 441 patients diagnosed with metastatic melanoma between 2011 and 2014 in the real-world setting at the University Hospital Tuebingen. METHODS: All patients were documented with their different therapies by the CMMR and followed up until March 2016...
November 22, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27863197/programmed-death-ligand-1-expression-and-response-to-the-anti-programmed-death-1-antibody-pembrolizumab-in-melanoma
#8
Adil I Daud, Jedd D Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S Weber, Antoni Ribas, F Stephen Hodi, Anthony M Joshua, Richard Kefford, Peter Hersey, Richard Joseph, Tara C Gangadhar, Roxana Dronca, Amita Patnaik, Hassane Zarour, Charlotte Roach, Grant Toland, Jared K Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S Peter Kang, Scot Ebbinghaus, Omid Hamid
Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks...
December 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27861496/clinical-characteristics-of-malignant-melanoma-in-southwest-china-a-single-center-series-of-82-consecutive-cases-and-a-meta-analysis-of-958-reported-cases
#9
Jia Yu, Xue Luo, Hui Huang, Zhifang Zhai, Zhu Shen, Hui Lin
PURPOSE: The present study determined the clinical characteristics and prognostic factors in patients with malignant melanoma based on a series of 82 cases from January 2009 to December 2014 in Southwest Hospital and a meta-analysis (including 12 articles) involving 958 patients in China. MATERIALS AND METHODS: The database elements included basic demographic data and prognosticators which were extracted from medical records. Statistical analyses of survival, and multivariate analyses of factors associated with survival were performed using the Kaplan-Meier method, and the Cox proportional hazard model, respectively...
2016: PloS One
https://www.readbyqxmd.com/read/27860480/-the-braf-mutation-and-the-possibilities-of-uveal-melanoma-metastasing-prognostic-markers-identification
#10
K Horkovičová, J Markus, I Krčová, P Babál, D Kobzová, B Smolková
AIM: The aim is to assess the BRAF gene mutations in patients with posterior uveal melanoma. MATERIAL AND METHODS: Retrospective analysis of the group of patients with malignant melanoma of the uvea, who were indicated to enucleation between 1.1 2015 to 1.3.2016. We analyzed stage of uveal melanoma, volume, cell type and BRAF gene mutations. RESULTS: In clinical study of 20 patients after enucleation due to uveal melanoma at the Department of Ophthalmology in Bratislava, patient age was ranged from 22 to 89 years with a median of 62 years...
2016: Ceská a Slovenská Oftalmologie
https://www.readbyqxmd.com/read/27846884/future-perspectives-in-melanoma-research-meeting-report-from-the-melanoma-bridge-napoli-december-1st-4th-2015
#11
Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, Alessandra Cesano, Gennaro Ciliberto, Michael A Davies, Sandra Demaria, Reinhard Dummer, Alexander M Eggermont, Soldano Ferrone, Yang Xin Fu, Thomas F Gajewski, Claus Garbe, Veronica Huber, Samir Khleif, Michael Krauthammer, Roger S Lo, Giuseppe Masucci, Giuseppe Palmieri, Michael Postow, Igor Puzanov, Ann Silk, Stefani Spranger, David F Stroncek, Ahmad Tarhini, Janis M Taube, Alessandro Testori, Ena Wang, Jennifer A Wargo, Cassian Yee, Hassane Zarour, Laurence Zitvogel, Bernard A Fox, Nicola Mozzillo, Francesco M Marincola, Magdalena Thurin
The sixth "Melanoma Bridge Meeting" took place in Naples, Italy, December 1st-4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's disease...
November 15, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27843913/quercetin-as-an-emerging-anti-melanoma-agent-a-four-focus-area-therapeutic-development-strategy
#12
REVIEW
Zoey Harris, Micah G Donovan, Gisele Morais Branco, Kirsten H Limesand, Randy Burd
Replacing current refractory treatments for melanoma with new prevention and therapeutic approaches is crucial in order to successfully treat this aggressive cancer form. Melanoma develops from neural crest cells, which express tyrosinase - a key enzyme in the pigmentation pathway. The tyrosinase enzyme is highly active in melanoma cells and metabolizes polyphenolic compounds; tyrosinase expression thus makes feasible a target for polyphenol-based therapies. For example, quercetin (3,3',4',5,7-pentahydroxyflavone) is a highly ubiquitous and well-classified dietary polyphenol found in various fruits, vegetables, and other plant products including onions, broccoli, kale, oranges, blueberries, apples, and tea...
2016: Frontiers in Nutrition
https://www.readbyqxmd.com/read/27843625/safety-and-immunogenicity-of-the-prame-cancer-immunotherapeutic-in-metastatic-melanoma-results-of-a-phase-i-dose-escalation-study
#13
R Gutzmer, L Rivoltini, E Levchenko, A Testori, J Utikal, P A Ascierto, L Demidov, J J Grob, R Ridolfi, D Schadendorf, P Queirolo, A Santoro, C Loquai, B Dreno, A Hauschild, E Schultz, T P Lesimple, N Vanhoutte, B Salaun, M Gillet, S Jarnjak, P M De Sousa Alves, J Louahed, V G Brichard, F F Lehmann
PURPOSE: The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. PATIENTS AND METHODS: Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic...
2016: ESMO Open
https://www.readbyqxmd.com/read/27818205/histopathologic-analysis-of-trans-vitreal-fine-needle-aspiration-biopsy-needle-tracts-for-uveal-melanoma
#14
Ryan S Kim, Patricia Chevez-Barrios, Maria E Bretana, Tien P Wong, Bin S Teh, Amy C Schefler
PURPOSE: Perform the first in vivo examination of fine needle aspiration biopsy scleral tracts to determine the incidence of iatrogenic extension of tumor cells. DESIGN: A prospective, consecutive, observational case series. METHODS: Setting: Clinical/surgical setting at Retina Consultants of Houston and Houston Methodist Hospital, Houston, TX. PARTICIPANTS: Ten patients who were scheduled for enucleation as primary treatment for uveal melanoma...
November 3, 2016: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27816830/adjuvant-ipilimumab-in-stage-iii-melanoma-new-landscape-new-questions
#15
Alexander M M Eggermont
The recently reported significant prolongation of overall survival with ipilimumab as adjuvant in high-risk stage III melanoma patients represents an important event in the adjuvant treatment landscape. The European Organisation for Research and Treatment of Cancer 18071 trial demonstrated a 28% reduction in risk of death in patients treated with ipilimumab at 10 mg/kg (hazard ratio for death, 0.72; 95.1% CI, 0.58-0.88; P = 0.001) compared with placebo. All end-points-recurrence-free survival (RFS), distant-metastasis-free survival (DMFS) and overall survival (OS)-showed similar benefits...
November 3, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27804026/patterns-and-timing-of-initial-relapse-in-pathologic-stage-ii-melanoma-patients
#16
Ann Y Lee, Nicolas Droppelmann, Katherine S Panageas, Qin Zhou, Charlotte E Ariyan, Mary S Brady, Paul B Chapman, Daniel G Coit
PURPOSE: Pathologic stage II melanoma patients have variable outcomes when divided by substage. We hypothesized that an understanding of the patterns of initial relapse by substage will better inform follow-up guidelines. METHODS: We performed a retrospective review of 738 adult patients with pathologic stage II cutaneous melanoma treated at Memorial Sloan Kettering Cancer Center between 1993 and 2013. Clinical records were reviewed to determine time, location, and method of detection of initial relapse...
November 1, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27793694/small-molecule-inhibition-of-polo-like-kinase-1-by-volasertib-bi-6727-causes-significant-melanoma-growth-delay-and-regression-in%C3%A2-vivo
#17
Brian D Cholewa, Mary A Ndiaye, Wei Huang, Xiaoqi Liu, Nihal Ahmad
The objective of this study was to determine the therapeutic potential of polo-like kinase 1 (Plk1) inhibition in melanoma, in vivo. Employing Vectra technology, we assessed the Plk1 expression profile in benign nevi, malignant (stages I-IV) and metastatic melanomas. We found a significant elevation of Plk1 immunostaining in melanoma tissues. Further, a second generation small molecule Plk1 inhibitor, BI 6727, resulted in reductions in growth, viability and clonogenic survival, as well as an increase in apoptosis of A375 and Hs 294T melanoma cells...
January 28, 2017: Cancer Letters
https://www.readbyqxmd.com/read/27774842/epidemiology-management-and-survival-outcomes-of-primary-cutaneous-melanoma-a-ten-year-overview
#18
M M F Aubuchon, L J J Bolt, M L G Janssen-Heijnen, S T H P Verleisdonk-Bolhaar, A van Marion, C L H van Berlo
BACKGROUND: Malignant melanoma (MM) is the most aggressive type of skin cancer, accounting for 90% of all the skin cancer mortality. The objective of this study was providing an overview of current patient- and tumour characteristics, treatment strategies, complications and survival in patients with MM over the past ten years. Hereby, an up-to-date view of every day clinical practice is obtained. METHODS: Files of patients treated for primary cutaneous melanoma (n = 686) in the VieCuri Medical Centre in the Netherlands between January 2002 and December 2013 were retrospectively reviewed...
October 23, 2016: Acta Chirurgica Belgica
https://www.readbyqxmd.com/read/27764805/nivolumab-for-advanced-melanoma-pretreatment-prognostic-factors-and-early-outcome-markers-during-therapy
#19
Yoshio Nakamura, Shigehisa Kitano, Akira Takahashi, Arata Tsutsumida, Kenjiro Namikawa, Keiji Tanese, Takayuki Abe, Takeru Funakoshi, Noboru Yamamoto, Masayuki Amagai, Naoya Yamazaki
BACKGROUND: An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune cell-derived markers and clinical predictors such as serum lactate dehydrogenase (LDH) and cutaneous adverse events, have already been described as prognostic factors for advanced melanoma treated with nivolumab. We sought to identify further clinical predictors that can be determined in routine clinical practice. METHODS: We retrospectively analyzed clinical findings of 98 consecutive patients with unresectable stage III or IV melanoma treated with nivolumab, at the National Cancer Center Hospital or at Keio University Hospital, in Tokyo, Japan, between July 2014 and July 2016...
October 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27760559/impact-of-aging-on-host-immune-response-and-survival-in-melanoma-an-analysis-of-3-patient-cohorts
#20
Sarah A Weiss, Joseph Han, Farbod Darvishian, Jeremy Tchack, Sung Won Han, Karolina Malecek, Michelle Krogsgaard, Iman Osman, Judy Zhong
BACKGROUND: Age has been reported as an independent prognostic factor for melanoma-specific survival (MSS). We tested the hypothesis that age impacts the host anti-tumor immune response, accounting for age-specific survival outcomes in three unique melanoma patient cohorts. METHODS: We queried the U.S. population-based Surveillance, Epidemiology, and End Results Program (SEER), the prospective tertiary care hospital-based Interdisciplinary Melanoma Cooperative Group (IMCG) biorepository, and the Cancer Genome Atlas (TCGA) biospecimen database to test the association of patient age at time of melanoma diagnosis with clinicopathologic features and survival outcomes...
October 19, 2016: Journal of Translational Medicine
keyword
keyword
62301
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"